B. Riley analyst Neil Chatterji raised the firm’s price target on Augmedix to $7.50 from $6.50 and keeps a Buy rating on the shares. The company reported a Q3 top-line beat and management increased its FY23 sales guidance, the analyst tells investors. The firm believes the top-line beat, continued GM expansion, and positive FY23 and Q4 outlooks are “encouraging” and should be well received.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AUGX:
- Augmedix reports Q3 EPS (10c), consensus (12c)
- Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023
- Is AUGX a Buy, Before Earnings?
- Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023
- Augmedix price target raised to $8 from $6 at Lake Street